Download PDF
TumorDiagnostik & Therapie 2021; 42(07): 486-498
DOI: 10.1055/a-1506-7865
Schwerpunkt Lymphome

Primäre Lymphome des zentralen Nervensystems

Sabine Seidel
,
Uwe Schlegel
› Further Information
Also available at
    Permissions and Reprints

Primäre ZNS-Lymphome sind Non-Hodgkin Lymphome des Gehirnparenchyms, der Meningen, und/oder des Rückenmarks mit fakultativer Beteiligung der Augen. Durch die Verfügbarkeit effektiver Chemotherapieprotokolle hat sich die Prognose dieser Tumoren insbesondere für jüngere Patienten in den letzten Jahrzehnten deutlich verbessert.

Publication History

Article published online:
30 August 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Ostrom QT, Cioffi G, Gittleman H. et al. CBTRUS Statistical Report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016. Neuro Oncol 2019; 21: v1-v100
    CrossrefPubMedGoogle Scholar
  • 2 Camilleri-Broët S, Martin A, Moreau A. et al. Primary central nervous system lymphomas in 72 immunocompetent patients: pathologic findings and clinical correlations. Groupe Ouest Est d’étude des Leucénies et Autres Maladies du Sang (GOELAMS). Am J Clin Pathol 1998; 110: 607-612
    CrossrefPubMedGoogle Scholar
  • 3 Mendez JS, Ostrom QT, Gittleman H. et al. The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades. Neuro Oncol 2018; 20: 687-694
    CrossrefPubMedGoogle Scholar
  • 4 Korfel A, Schlegel U. Diagnosis and treatment of primary CNS lymphoma. Nat Rev Neurol 2013; 9: 317-327
    CrossrefPubMedGoogle Scholar
  • 5 Küker W, Nägele T, Korfel A. et al. Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. J Neurooncol 2005; 72: 169-177
    CrossrefPubMedGoogle Scholar
  • 6 Hoang-Xuan K, Bessell E, Bromberg J. et al. Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. Lancet Oncol 2015; 16: e322-e3232
    CrossrefPubMedGoogle Scholar
  • 7 Ferreri AJ, Reni M, Foppoli M. et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 2009; 374: 1512-1520
    CrossrefPubMedGoogle Scholar
  • 8 Thiel E, Korfel A, Martus P. et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, noninferiority trial. Lancet Oncol 2010; 11: 1036-1047
    CrossrefPubMedGoogle Scholar
  • 9 Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: the next step. J Clin Oncol 2000; 18: 3144-3150
    CrossrefPubMedGoogle Scholar
  • 10 Morris PG, Correa DD, Yahalom J. et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: Final results and long-term outcome. J Clin Oncol 2013; 31: 3971-3979
    CrossrefPubMedGoogle Scholar
  • 11 Bromberg JEC, Issa S, Bakunina K. et al. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study. Lancet Oncol 2019; 20: 216-228
    CrossrefPubMedGoogle Scholar
  • 12 Illerhaus G, Kasenda B, Ihorst G. et al. High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. Lancet Haematol 2016; 3: e388-e397
    CrossrefPubMedGoogle Scholar
  • 13 Houillier C, Taillandier L, Dureau S. et al. Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: Results of the intergroup ANOCEF-GOELAMS randomized phase II PRECIS study. J Clin Oncol 2019; 37: 823-833
    CrossrefPubMedGoogle Scholar
  • 14 Ferreri AJM, Cwynarski K, Pulczynski E. et al. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal L. Lancet Haematol 2017; 4: e510-e523
    CrossrefPubMedGoogle Scholar
  • 15 Ferreri AJM, Cwynarski K, Pulczynski E. et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: Results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol 2016; 3: e217-e227
    CrossrefPubMedGoogle Scholar
  • 16 Juergens A, Pels H, Rogowski S. et al. Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma. Ann Neurol 2010; 67: 182-189
    CrossrefPubMedGoogle Scholar
  • 17 Seidel S, Pels H, Schlömer S. et al. Twenty years follow-up of a pilot/phase II-trial on the Bonn protocol for primary CNS lymphoma. Neurology 2020; 95: e3138-e3144 DOI: 10.1212/WNL.0000000000010949.
    CrossrefPubMedGoogle Scholar
  • 18 Rubenstein JL, Hsi ED, Johnson JL. et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol 2013; 31: 3061-3068
    CrossrefPubMedGoogle Scholar
  • 19 Nelson DF. Radiotherapy in the treatment of primary central nervous system lymphoma (PCNSL). Journal of Neuro-Oncology 1999; 43: 241-247
    CrossrefPubMedGoogle Scholar
  • 20 Kasenda B, Ferreri AJM, Marturano E. et al. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)-a systematic review and individual patient data meta-analysis. Ann Oncol Off J Eur Soc Med Oncol 2015; 26: 1305-1313
    CrossrefPubMedGoogle Scholar
  • 21 Omuro A, Chinot O, Taillandier L. et al. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. Lancet Haematol 2015; 2: e251-e259
    CrossrefPubMedGoogle Scholar
  • 22 Fritsch K, Kasenda B, Schorb E. et al. High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). Leukemia 2017; 31: 846-852
    CrossrefPubMedGoogle Scholar
  • 23 Houillier C, Ghesquières H, Chabrot C. et al. Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study. J Neurooncol 2017; 133: 315-320
    CrossrefPubMedGoogle Scholar
  • 24 Hoang-Xuan K, Taillandier L, Chinot O. et al. Chemotherapy Alone as Initial Treatment for Primary CNS Lymphoma in Patients Older Than 60 Years: A Multicenter Phase II Study (26952) of the European Organization for Research and Treatment of Cancer BrainTumor Group. J Clin Oncol 2003; 21: 2726-2731
    CrossrefPubMedGoogle Scholar
  • 25 Pulczynski EJ, Kuittinen O, Erlanson M. et al. Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group. Haematologica 2015; 100: 534-540
    CrossrefPubMedGoogle Scholar
  • 26 Seidel S, Kowalski T, Margold M. et al HDMTX-based polychemotherapy including intraventricular therapy in elderly patients with primary CNS lymphoma: a single center series. Ther Adv Neurol Disord 2020; 13
    PubMedGoogle Scholar
  • 27 Omuro AMP, Taillandier L, Chinot O. et al. Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. J Neurooncol 2007; 85: 207-211
    CrossrefPubMedGoogle Scholar
  • 28 Taylor AL, Marcus R, Bradley JA. et al. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol Hematol 2005; 56: 155-167
    CrossrefPubMedGoogle Scholar
  • 29 Kaulen LD, Karschnia P, Dietrich J. et al. Autoimmune disease-related primary CNS lymphoma: systematic review and meta-analysis. J Neurooncol 2020; 149: 153-159
    CrossrefPubMedGoogle Scholar
  • 30 Fischer L, Thiel E, Klasen HA. et al. Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann Oncol 2006; 17: 1141-1145
    CrossrefPubMedGoogle Scholar
  • 31 Voloschin AD, Betensky R, Wen PY. et al. Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma. J Neurooncol 2008; 86: 211-215
    CrossrefPubMedGoogle Scholar
  • 32 Reni M, Zaja F, Mason W. et al. Temozolomide as salvage treatment in primary brain lymphomas. Br J Cancer 2007; 96: 864-867
    CrossrefPubMedGoogle Scholar
  • 33 Enting RH, Demopoulos A, DeAngelis LM. et al. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 2004; 63: 901-903
    CrossrefPubMedGoogle Scholar
  • 34 Mappa S, Marturano E, Licata G. et al. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy. Hematol Oncol 2013; 31: 143-150
    CrossrefPubMedGoogle Scholar
  • 35 Soussain C, Hoang-Xuan K, Taillandier L. et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. J Clin Oncol 2008; 26: 2512-2518
    CrossrefPubMedGoogle Scholar
  • 36 Kasenda B, Ihorst G, Schroers R. et al. High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group. Leukemia 2017; 31: 2623-2629
    CrossrefPubMedGoogle Scholar
  • 37 Ghesquieres H, Chevrier M, Laadhari M. et al. Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective “proof of concept” phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA). Ann Oncol 2019; 30: 621-628
    CrossrefPubMedGoogle Scholar
  • 38 Korfel A, Schlegel U, Herrlinger U. et al. Phase II Trial of Temsirolimus for Relapsed/Refractory Primary CNS Lymphoma. J Clin Oncol 2016; 34: 1757-1763
    CrossrefPubMedGoogle Scholar
  • 39 Grommes C, Nayak L, Tun HW. et al. Introduction of novel agents in the treatment of primary CNS lymphoma. Neuro Oncol 2019; 21: 306-313
    CrossrefPubMedGoogle Scholar